The work in this study suggests that it may be possible to use proteomic measurements from bulk samples to assess the degree of myeloid infiltration in a tumor, through either the detection of neutrophil granule proteases (e.g., ELANE–PRTN3) directly or the detection of nontryptic peptides generated by these active myeloid serine proteases. This evidence concerns the gene PRTN3 and neoplasm.